GM1 Gangliosidosis Treatment Market, By Product Type, By Disease Type, By Geography

Description

Gm1 Gangliosidosis Treatment Market is estimated to be valued at USD 194.2 Mn in 2026 and is expected to reach USD 1,658.9 Mn by 2033, growing at a compound annual growth rate (CAGR) of 36.7% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 194.2 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	36.70%	2033 Value Projection:	USD 1,658.9 Mn

GM1 gangliosidosis is a progressive neurological genetic disorder mainly caused by the absence of a vital enzyme known as beta-galactosidase (GLB1). Without GLB1, a fatty substance called GM1 gangliosidosis accumulates in cells, and nerve cells of the brain. GM1 gangliosidosis is one of the 50 genetically inherited disorders known as lysosomal storage diseases. Currently, there is no treatment or cure for treatment of GM1 gangliosidosis.

Market Dynamics

Key players are focusing on strategic agreements in order to expand their presence in the market. For instance, in May 2017, Lysogene entered a strategic manufacturing agreement with Brammer Bio, a viral gene and cell therapy manufacturer. The agreement is expected to help Brammer Bio manufacture LYS-GM101, an AAVrh10- based gene therapy for the treatment of GM1 gangliosidosis.

Key features of the study

This report studies the current scenario as well as the future potential of the global GM1 gangliosidosis market. The market for GM1 gangliosidosis is segmented on the basis of product type, disease type, and region.
This report provides in-depth analysis of the global GM1 gangliosidosis market, and provides market size (USD Mn) and compound annual growth rate (CAGR) (%) for the forecast period (2026-2033)
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market. It provides valuable insights about market drivers, restraints, opportunities, country outlook, and competitive strategies adopted by the leading players.
It profiles leading players in the global GM1 gangliosidosis market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, key developments, and future plans
Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future market expansion and marketing tactics
The global GM1 gangliosidosis market report caters to various stakeholders in this industry, including investors, product developers and manufacturers, distributors, healthcare organizations, research institutes, new entrants, and financial analysts
Stakeholders would greatly benefit in decision making through various strategy matrices used in analyzing the global GM1 gangliosidosis market

Gm1 Gangliosidosis Treatment Market Segmentation

By Product Type
- LYS-GM101
- PBGM01
- AXO-AAV-GM1
By Disease Type
- Type 1 GM1 Gangliosidosis
- Type 2 GM1 Gangliosidosis
- Type 3 GM1 Gangliosidosis
Global Gm1 Gangliosidosis Treatment Market, By Region
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
Competitive Landscape
Company Profiles
- Axovant Gene Therapies Ltd.
- Passage Bio
- Lysogene

Product Code: CMI4270

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Product Type
- Market Snapshot, By Disease Type
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Drivers
Restraints
Market Opportunities
Impact Analysis
Pipeline Analysis
Regulatory Scenario
Key Development
Epidemiology
Primary Research Insights
- Patient Insights
- Physician Insights
- Manufacturer Insights

4. Global GM1 Glangliosidosis Treatment Market, By Product Type, 2021-2033 (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
LYS-GM101
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
PBGM01
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
AXO-AAV-GM1
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

5. Global GM1 Glangliosidosis Treatment Market, By Disease Type, 2021-2033 (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Type 1 GM1 Gangliosidosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Type 2 GM1 Gangliosidosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Type 3 GM1 Gangliosidosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

6. Global GM1 Glangliosidosis Treatment Market, By Region, 2021-2033 (USD Mn)

Introduction
- Market Share Analysis, By Country, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Countries, 2022-2033
North America
- Introduction
- Market Size and Forecast, By Product Type, 2021-2033 (USD Mn)
- Market Size and Forecast, By Disease Type, 2021-2033 (USD Mn)
- Market Size and Forecast, By Country, 2021-2033 (USD Mn)
  - U.S.
  - Canada
Europe
- Introduction
- Market Size and Forecast, By Product Type, 2021-2033 (USD Mn)
- Market Size and Forecast, By Disease Type, 2021-2033 (USD Mn)
- Market Size and Forecast, By Country, 2021-2033 (USD Mn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Latin America
- Introduction
- Market Size and Forecast, By Product Type, 2021-2033 (USD Mn)
- Market Size and Forecast, By Disease Type, 2021-2033 (USD Mn)
- Market Size and Forecast, By Country, 2021-2033 (USD Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Asia Pacific
- Introduction
- Market Size and Forecast, By Product Type, 2021-2033 (USD Mn)
- Market Size and Forecast, By Disease Type, 2021-2033 (USD Mn)
- Market Size and Forecast, By Country, 2021-2033 (USD Mn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Product Type, 2021-2033 (USD Mn)
- Market Size and Forecast, By Disease Type, 2021-2033 (USD Mn)
- Market Size and Forecast, By Country, 2021-2033 (USD Mn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Product Type, 2021-2033 (USD Mn)
- Market Size and Forecast, By Disease Type, 2021-2033 (USD Mn)
- Market Size and Forecast, By Country, 2021-2033 (USD Mn)
  - Central Africa
  - South Africa
  - North Africa

7. Competitive Landscape

Company Profiles
- Axovant Gene Therapies Ltd.
  - Company Overview
  - Clinical Trial Phase Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- Passage Bio
  - Company Overview
  - Clinical Trial Phase Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- Lysogene
  - Company Overview
  - Clinical Trial Phase Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies